Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent before the initiation of any study related procedures and continues to give willing consent for participation~* Age ≥ 40 years~* Have had upper extremity tremor for \< 3 years duration, regardless of presumed diagnosis or etiology~* Have a UPDRS part III score upon entry of ≤ 16~Exclusion Criteria:~* Any clinically significant or unstable physical or psychological illness based on medical history or physical examination at screening, as determined by the investigator~* Structural brain abnormality affecting the entire brain (e.g., normal pressure hydrocephalus) or the striatum (e.g., local tumor or stroke)~* Any clinically significant abnormal laboratory results obtained at screening and as determined by the investigator~* Any clinically significant abnormal electrocardiogram (ECG) results obtained at screening and as determined by the investigator~* Any history of drug, narcotic, or alcohol abuse within 2 years before the date of informed consent, as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, Fourth Edition, revised (DSM-IV-TR \[American Psychiatric Association, 1994\])~* Positive urine drug screen for opiates, cocaine, or amphetamines at screening~* Positive pregnancy test before imaging~* Participation in an investigational drug or device clinical trial within 30 days before the date of informed consent~* Previous scan with any DAT imaging agent (e.g. \[123I\]NAV5001, Altropane, DaTscan, DOPASCAN)~* Any exposure to radiopharmaceuticals within 30 days before the date of informed consent~* Breast-feeding~* Inability to lie supine for 1 hour~* Any thyroid disease other than adequately treated hypothyroidism~* Known sensitivity or allergy to iodine or iodine containing products~* Treatment within the 30 days before the date of imaging with amoxapine, amphetamine, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline, paroxetine, or citalopram.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAV5001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).